Log in to search using one of your social media accounts:

 

Another SGLT2 Drug Shines as Insulin Adjunct in T1D (CME/CE)
(MedPage Today) -- Dapagliflozin lowered HbA1c in phase III trial (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 14, 2017 Category: Cardiology Source Type: news

InTandem3: Sotagliflozin Has Benefits and Risks in Type 1 Diabetes InTandem3: Sotagliflozin Has Benefits and Risks in Type 1 Diabetes
The largest of three phase 3 studies of the novel investigational SGLT1/SGLT2 inhibitor shows that it improves glycemic control and may reduce body weight and BP but also raises some risks, including DKA.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 and DPP-4 Inhibition SGLT2 and DPP-4 Inhibition
What role could combination therapy with these inhibitors play in the management of type 2 diabetes?Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 1, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

AKI Risk with SGLT2 Inibitors? Maybe Not, Clinic Data Show AKI Risk with SGLT2 Inibitors? Maybe Not, Clinic Data Show
Despite FDA warnings of a possible increased risk for AKI with the SGLT2 inhibitors, a new analysis of two large databases finds no evidence of elevated risk.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 28, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Retrospective review of SGLT2 inhibitor exposures reported to 13 poison centers - Schaeffer SE, DesLauriers C, Spiller HA, Aleguas A, Baeza S, Ryan ML.
BACKGROUND: SGLT2 inhibitors are a new class of oral antidiabetics prescribed in the United States since 2013. They act by inhibiting reabsorption of glucose in the proximal convoluted tubule of the kidney, allowing excess glucose to be excreted. Little ha... (Source: SafetyLit)
Source: SafetyLit - August 25, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Do SGLT2 Inhibitors ’ Heart Failure Benefits Involve Sodium-hydrogen Exchanger? Do SGLT2 Inhibitors ’ Heart Failure Benefits Involve Sodium-hydrogen Exchanger?
Sodium-glucose cotransporter 2 (SGLT2) inhibitors may reduce cardiovascular events via interaction with the sodium-hydrogen exchanger, researchers suggest.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 14, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine News Source Type: news

Positive Cardiac Biomarker Changes Seen With Canagliflozin in T2D Positive Cardiac Biomarker Changes Seen With Canagliflozin in T2D
Canagliflozin suppressed the increase in NT-proBNP and high-sensitivity troponin in older patients with type 2 diabetes, which may help shed some light on the beneficial CV effect of SGLT2 inhibitors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Agents Cut CV Events in'Real-World' Analysis
(MedPage Today) -- Scandinavian data show reductions in cardiovascular mortality and HF hospitalizations (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 7, 2017 Category: Cardiology Source Type: news

More Evidence Empagliflozin Protects the Kidneys More Evidence Empagliflozin Protects the Kidneys
New data from the EMPA-REG-OUTCOME study provide more evidence of the renoprotective effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with type 2 diabetes and cardiovascular disease.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 10, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

New Drug Classes for Diabetes Mean New Options New Drug Classes for Diabetes Mean New Options
Dr Cyrus Desouza reviews GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors, offering advice on which patients may benefit from each class.Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 30, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

SGLT1/2 Inhibitor Sotagliflozin'Encouraging' in Type 1 Diabetes SGLT1/2 Inhibitor Sotagliflozin'Encouraging' in Type 1 Diabetes
The investigational, oral agent sotagliflozin, a first-in-class, oral dual inhibitor of both SGLT1 and SGLT2, is in phase 3 trials in type 1 diabetes; results are promising but there are some caveats.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 22, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

ADA 2017: Evaluating Cardiovascular Safety of Antidiabetic Agents
Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017. (Source: ConsultantLive)
Source: ConsultantLive - June 14, 2017 Category: Internal Medicine Authors: Kenneth J. Bender, PharmD, MA Tags: Conferences/ADA 2017 Diabetes Diabetes Type 2 Source Type: news

CANVAS: Canagliflozin Reduces CV Events, but at Cost of Amputations CANVAS: Canagliflozin Reduces CV Events, but at Cost of Amputations
Pooled data from two CANVAS trials suggest that cardioprotection is likely a class effect with SGLT2 inhibitors, but it comes at the price of toe amputations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes
Sotagliflozin Demonstrates Statistically Significant Benefit in Primary Endpoint Results Support a Unique Drug Profile as an SGLT1 and SGLT2 Inhibitor THE WOODLANDS, Texas, June 9, 2017 -- (Healthcare Sales & Marketing Network) -- Lexicon Pharmaceut... Biopharmaceuticals, Endocrinology Lexicon Pharmaceuticals, sotagliflozin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 9, 2017 Category: Pharmaceuticals Source Type: news

Study Warns of Diabetic Ketoacidosis With SGLT2 Inhibitors in T2D (CME/CE)
(MedPage Today) -- Doubled risk compared with DPP4 inhibitors (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 7, 2017 Category: Primary Care Source Type: news

SGLT2 Inhibitors Double the Risk for Diabetic Ketoacidosis SGLT2 Inhibitors Double the Risk for Diabetic Ketoacidosis
The risk for diabetic ketoacidosis is roughly twofold for type 2 diabetes patients initiating SGLT2 inhibitors compared with DPP-4 inhibitors, but the overall absolute risk remains low.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Study Confirms Link Between SGLT2 inhibitors and Diabetic Ketoacidosis
WEDNESDAY, June 7, 2017 -- A new class of type 2 diabetes drugs called SGLT2 inhibitors could increase the risk of a rare, life-threatening complication of the disease called ketoacidosis, a new study warns. SGLT2 inhibitors include prescription... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 7, 2017 Category: General Medicine Source Type: news

Study Confirms Link Between Diabetes Med and Rare But Dangerous Complication
WEDNESDAY, June 7, 2017 -- A new class of type 2 diabetes drugs called SGLT2 inhibitors could increase the risk of a rare, life-threatening complication of the disease called ketoacidosis, a new study warns. SGLT2 inhibitors include prescription... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 7, 2017 Category: General Medicine Source Type: news

New Class of Type 2 Diabetes Drug Associated with Rare, Life-Threatening Outcome
Investigators quantify risk of diabetic ketoacidosis for patients taking SGLT2 inhibitors (Source: BWH for Journalists)
Source: BWH for Journalists - June 7, 2017 Category: Research Source Type: news

UK NICE Elevates SGLT2 Inhibitors in Diabetes Guidance UK NICE Elevates SGLT2 Inhibitors in Diabetes Guidance
The sodium-glucose cotransporter 2 (SGLT2) inhibitor class is now listed clearly as a second-line option after metformin in type 2 diabetes.Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 26, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Oral Agents and Insulin: What, and for How Long? Oral Agents and Insulin: What, and for How Long?
Drs Shubrook and Healy discuss optimal patient approaches to balancing insulin, SGLT2 inhibitors, and oral agents in the management of uncontrolled type 2 diabetes.Medscape Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 24, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care Commentary Source Type: news

Registry Confirms Low Risk of DKA With SGLT2 Inhibitors in Diabetes Registry Confirms Low Risk of DKA With SGLT2 Inhibitors in Diabetes
Danish registry data suggest diabetic ketoacidosis risk is slightly but not significantly elevated among type 2 diabetes patients using the drug class.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 21, 2017 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes
Dateline City: KENILWORTH, N.J.& NEW YORK Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA® (sitagliptin) or MetforminKENILWORTH, N.J.& NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S.Language: EnglishContact: Merck Media:Doris Li, (908) 246-5701orMerck Investor:Amy Klug, (908) 740-1898orKristen Drake, (908) 236-4223orPfizer Media:Steve Danehy, (212) 733-1538orPfizer Investor:Ryan Crowe, (212) 733-8160Ticker Slug:Ticker:MRKExchange:NYSET...
Source: Merck.com - Research and Development News - March 6, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK #Pfizer $MRK $PFE Januvia MSD NYSE:MRK Source Type: news

FDA Finally OKs Dapagliflozin/Saxagliptin for Type 2 Diabetes FDA Finally OKs Dapagliflozin/Saxagliptin for Type 2 Diabetes
After first rejecting it at the end of 2015, the FDA has now approved the AstraZeneca DPP-4 inhibitor/SGLT2 inhibitor fixed-dose combination product Qtern for type 2 diabetes in adults.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 28, 2017 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Monthly News Roundup - February 2017
FDA Approves Once-Daily Qtern Tablets for Adults with Type 2 Diabetes The U.S. Food and Drug Administration (FDA) has cleared AstraZeneca’s Qtern (dapagliflozin and saxagliptin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2017 Category: Pharmaceuticals Source Type: news

EMA: Amputation Warning With SGLT2 Inhibitors Must Be on Label EMA: Amputation Warning With SGLT2 Inhibitors Must Be on Label
Lower-limb (mostly toe) amputation risk seen in canagliflozin clinical trials, but EMA panel says all SGLT2 inhibitors should carry the label warning.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 10, 2017 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

NSAIDs With SGLT2 Inhibitors in Diabetes May Cause Renal Injury NSAIDs With SGLT2 Inhibitors in Diabetes May Cause Renal Injury
The authors point to evidence linking SGLT2 inhibitors for diabetes with hypoxic kidney damage if patients are dehydrated or when the agents are used concomitantly with NSAIDs or during radiocontrast studies.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - January 31, 2017 Category: Emergency Medicine Tags: Diabetes & Endocrinology News Source Type: news

Do Low-Carb Diets Cause Diabetic Ketoacidosis With SGLT2 Inhibitors? Do Low-Carb Diets Cause Diabetic Ketoacidosis With SGLT2 Inhibitors?
The study is first to investigate the association of low-carb diets and"euglycemic DKA" reported in people with type 2 diabetes on SGLT2 inhibitors.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 25, 2017 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Randomized trial will reveal diabetes drug's effects on kidney health
(Wiley) Type 2 diabetes often causes damaging effects to the kidneys, sometimes resulting in the need for dialysis or kidney transplantation. The ongoing CANVAS-R trial is testing whether canagliflozin -- a member of a new class of diabetes treatments known as sodium glucose co-transporter 2 (SGLT2) inhibitors -- can slow kidney function decline and provide other benefits to diabetic patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 25, 2017 Category: Global & Universal Source Type: news

SGLT2 Inhibition for Reducing CVD Events in High-Risk T2DM SGLT2 Inhibition for Reducing CVD Events in High-Risk T2DM
This review examines the potential mechanisms by which SGLT2 inhibitors might impact cardiovascular risk. What role might they play in the treatment of diabetic patients at high CVD risk?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 3, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Empagliflozin Wins CV Prevention Indication
(MedPage Today) -- FDA approves claim that SGLT2 inhibitor reduces cardiovascular death risk (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 2, 2016 Category: Cardiology Source Type: news

ASN: SGLT2 Inhibitor May Slow eGFR Decline in T2D (CME/CE)
(MedPage Today) -- Uniform treatment effect across entire distribution of renal function (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - November 22, 2016 Category: Consumer Health News Source Type: news

SGLT2 Inhibitors (Sodium-Glucose Co-Transporter 2, Type 2 Diabetes Drug Class)
Title: SGLT2 Inhibitors (Sodium-Glucose Co-Transporter 2, Type 2 Diabetes Drug Class)Category: MedicationsCreated: 11/3/2016 12:00:00 AMLast Editorial Review: 11/3/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - November 3, 2016 Category: Endocrinology Source Type: news

SGLT2 Inhibitors (Sodium-Glucose Co-Transporter 2)
Title: SGLT2 Inhibitors (Sodium-Glucose Co-Transporter 2)Category: MedicationsCreated: 11/3/2016 12:00:00 AMLast Editorial Review: 11/3/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - November 3, 2016 Category: Endocrinology Source Type: news

First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes
Exenatide once weekly combined with daily dapagliflozin improved glycemic outcomes, BP, and weight loss more than each drug alone in DURATION-8, the first trial to examine a combination of these 2 agents.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 20, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

EASD: After Metformin Failure, SGLT2/GLP-1 Combo Works (CME/CE)
(MedPage Today) -- Superior glycemic control, weight loss versus either agent alone (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - September 19, 2016 Category: Urology & Nephrology Source Type: news

EASD: Novel SGLT2 Drug Works in Triple Therapy (CME/CE)
(MedPage Today) -- Ertugliflozin improved T2D control atop metformin/sitagliptin (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - September 15, 2016 Category: Urology & Nephrology Source Type: news

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
Dateline City: KENILWORTH, N.J., and NEW YORK, N.Y.New Phase 3 Data Presented at the European Association for the Study of Diabetes Annual Meeting – Study Achieved Primary and All Key Secondary EndpointsKENILWORTH, N.J., and NEW YORK, N.Y. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint.Language: Englishread more (Source: Merck.com - Research and Development News)
Source: Merck.com - Research and Development News - September 15, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

New Diabetes Drugs May Also Improve Kidney Health
The renal protective effects seen with the SGLT2 inhibitor canogliflizin may be independent of glycemic control, suggest authors of a new post-hoc analysis. (Source: ConsultantLive)
Source: ConsultantLive - August 25, 2016 Category: Internal Medicine Authors: Scott Harris Source Type: news

New Diabetes Drugs May Also Improve Kidney Health (CME/CE)
(MedPage Today) -- SGLT2 inhibitors shown to slow declines in renal function (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 19, 2016 Category: Primary Care Source Type: news

Diabetes Drugs: The Latest Good -- and Bad -- News Diabetes Drugs: The Latest Good -- and Bad -- News
Dr Anne Peters discusses hot topics in type 2 diabetes treatment: liraglutide shows CV benefits, whereas some SGLT2 inhibitors show renal protection -- and potential harm.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 16, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news

EMA Extends Amputation Investigation to All SGLT2 InhibitorsEMA Extends Amputation Investigation to All SGLT2 Inhibitors
In a revision of its April 2016 notice regarding canagliflozin and amputations, the EMA's Pharmacovigilance Risk Assessment Committee is now investigating all drugs in the class. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 8, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitor Adds to Weight Loss With Phentermine (CME/CE)
(MedPage Today) -- Canagliflozin may have synergistic effect with standard obesity drug (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 15, 2016 Category: Cardiology Source Type: news

AstraZeneca Combo for Type 2 Diabetes Gets Green Light in EUAstraZeneca Combo for Type 2 Diabetes Gets Green Light in EU
The EMA has given the green light to a fixed-dose combination of saxagliptin and dapagliflozin, the first combination of DPP-4/SGLT2 inhibitor in Europe, for the treatment of type 2 diabetes. International Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 27, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

Canagliflozin in Individuals Aged 75 and Older With T2DMCanagliflozin in Individuals Aged 75 and Older With T2DM
Is the SGLT2 inhibitor canagliflozin safe to use in elderly diabetic patients? Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 21, 2016 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

EMA Probes Link With Diabetes Drug Canagliflozin, Toe AmputationEMA Probes Link With Diabetes Drug Canagliflozin, Toe Amputation
The European Medicines Agency is reviewing the type 2 diabetes drug canagliflozin, an SGLT2 inhibitor, after an increase in toe amputations was observed in the ongoing CANVAS trial. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 15, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Canagliflozin in T1D Has Ketoacidosis Problem (CME/CE)
(MedPage Today) -- SGLT2 inhibitor effective but risky in type 1 patients (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 17, 2016 Category: Cardiology Source Type: news

Timely Access: The Waiting Game
Innovation in pharma is in itself a complex and drawn-out process – where inspiration and perspiration merge over years to produce a novel compound or molecule that will benefit human health. Yet while this process has been increasingly streamlined as science and technology progresses, drug approval processes remain a painstaking process that can significantly delay access to groundbreaking and effective therapies. Despite the central role of industry in healthcare delivery, outcomes and development, innovation in the form of lifesaving or life-prolonging medicines is now being scuppered by lengthy gaps between marke...
Source: EyeForPharma - February 25, 2016 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news

SGLT2 inhibitors and diabetic ketoacidosis
The European Medicines Agency (EMA) urges healthcare professionals to be aware of signs of diabetic ketoacidosis (DKA) in people with type 2 diabetes who are taking SGLT2 inhibitors. Diabetes.co.uk (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 23, 2016 Category: Endocrinology Source Type: news

EMA on Lowering Risk of Diabetic Ketoacidosis With SGLT2 InhibitorsEMA on Lowering Risk of Diabetic Ketoacidosis With SGLT2 Inhibitors
The EMA completes review of risk of diabetic ketoacidosis with the use of SGLT2 inhibitors in type 2 diabetes and urges medics to look out for atypical presentation with only mildly elevated glucose levels. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 12, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news